ROCKET PHARMACEUTICALS, INC.
RCKTWDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
FDA PDUFA Date RP-L102 (priority)
For Fanconi anemia. BLA filing. Extracted from SEC filing: 8-K
Source| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
RP-L102 | Phase 2 | Fanconi Anemia Complementation Group A | - | - |
Frequently asked questions
What is in ROCKET PHARMACEUTICALS, INC.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in ROCKET PHARMACEUTICALS, INC.'s (RCKTW) pipeline across Phase 2. Its lead program is RP-L102 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is ROCKET PHARMACEUTICALS, INC.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for ROCKET PHARMACEUTICALS, INC. (RCKTW) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track RCKTW biotech catalysts?→
Add RCKTW to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow ROCKET PHARMACEUTICALS, INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.